Selected vfa bio articles in English language

The new biotech report describing the situation of medical biotechnology in Germany is now available. The focus of this year’s report is on the benefit of biopharmaceuticals for patients with autoimmune diseases.

Read on 

Given the large number of orphan diseases and because of the huge medical need for new therapeutic options especially for people with rare diseases, there is still a very great deal of work to be done in this area. vfa and vfa bio are strongly committed to rigorously promoting the development of new therapies for orphan diseases throughout the value chain.

 Download

By international comparison, Germany holds a strong position in the field of nanotechnology, a cross-sectional technology, implemented in many different fields. Nanobiotechnology, or the application in areas of medicine, pharmacy and life sciences to be precise, has the potential of opening up new or improved/earlier diagnostic or therapeutic opportunities for diseases that were previously insufficiently curable or completely incurable.

 Download

vfa and vfa bio, representing biopharmaceutical companies with and without biosimilar activities, are committed to competition between biopharmaceutical therapy options so as to improve health care for patients. We advocate for general conditions for the quality-assured use of bio-pharmaceuticals - original products and biosimilars:

 Download

The new biotech report describing the situation of medical biotechnology in Germany is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies. In addition to key economic data on medical biotechnology in Germany in 2017, the focus of this year’s report is on the production of biopharmaceuticals as well as on the benefit of biopharmaceuticals for patients with metabolic diseases.

Read on 

The new biotech report describing the situation of medical biotechnology in Germany is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies. In addition to key economic data on medical biotechnology in Germany in 2016, the focus of this year’s report is on oncology.

Read on 

The new biotech report describing the situation of medical biotechnology in Germany is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies.

Read on 

A brief summary of the key economic data in medical biotechnology in Germany, a ten-year comparison and seven assumptions on developments, which are likely to shape the biopharmaceutical industry over the course of the next ten years.

Read on